Aileron Therapeutics Inc. (ALRN)

Name: Aileron Therapeutics Inc. (ALRN) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Aileron Therapeutics Inc. (ALRN)

Stock Card

$2.05

$-0.06 (-2.84%)

As on 07-Feb-2025 09:30EDT

Market cap

$46 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

0.9

Div. Yield

0 %

Aileron Therapeutics (ALRN) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 2.00 High: 2.30

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.4 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.6
Debt to Equity

0
Book Value

$--
EPS

$--
Face value

--
Shares outstanding

21,665,900

10 Years Aggregate

CFO

$-207.79 Mln

EBITDA

$-204.13 Mln

Net Profit

$-220.28 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Aileron Therapeutics (ALRN)	-10.9	-1.9	-46.6	-52.7	-38.7	-32.5	--
BSE Sensex^*	-10.7	-3.7	1.8	-6.4	4.5	5.3	10.1
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 07-Feb-2025 | *As on 08-Sep-2026 | #As on 26-Oct-2023

Company	2024	2023	2022	2021	2020	2019	2018
Aileron Therapeutics (ALRN)	-24.4	28.6	-98.9	-45.9	81.5	-31.8	-91.9
S&P Small-Cap 600	7.0	13.9	-17.4	25.3	9.6	20.9	-9.7
BSE Sensex	8.1	18.7	4.4	22.0	15.8	14.4	5.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Aileron Therapeutics (ALRN)

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide,... which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas. Read more

CEO & Director

Dr. James Brian Windsor Ph.D.
CEO & Director

Dr. James Brian Windsor Ph.D.
Headquarters

Austin, TX
Website

https://www.aileronrx.com

FAQs for Aileron Therapeutics (ALRN)

What is the current share price of Aileron Therapeutics Inc (ALRN) Today?

The share price of Aileron Therapeutics Inc (ALRN) is $2.05 (NASDAQ) as of 07-Feb-2025 09:30 EDT. Aileron Therapeutics Inc (ALRN) has given a return of -38.65% in the last 3 years.

What is the current PB & PE ratio of Aileron Therapeutics Inc (ALRN)?

Since, TTM earnings of Aileron Therapeutics Inc (ALRN) is negative, P/E ratio is not available.
The P/B ratio of Aileron Therapeutics Inc (ALRN) is 0.88 times as on 07-Feb-2025, a 83 discount to its peers’ median range of 5.33 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2023	--	--
2022	--	--
2021	--	--
2020	--	--
2019	--	--

What is the 52 Week High and Low of Aileron Therapeutics Inc (ALRN)?

The 52-week high and low of Aileron Therapeutics Inc (ALRN) are Rs -- and Rs -- as of 08-Sep-2026.

What is the market cap of Aileron Therapeutics Inc (ALRN)?

Aileron Therapeutics Inc (ALRN) has a market capitalisation of $ 46 Mln as on 07-Feb-2025. As per SEBI classification, it is a Small Cap company.

Should I invest in Aileron Therapeutics Inc (ALRN)?

Before investing in Aileron Therapeutics Inc (ALRN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.